PHP
BCRX icon

Parkman Healthcare Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Parkman Healthcare Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.3M Buy
1,708,099
+808,042
+90% +$6.28M 1.68% 20
2025
Q4 		$7.02M Sell
900,057
-112,607
-11% -$814K 0.67% 48
2025
Q3 		$7.69M Buy
1,012,664
+4,672
+0.5% +$38.9K 0.8% 46
2025
Q2 		$9.03M Buy
1,007,992
+7,430
+0.7% +$69.2K 1.04% 32
2025
Q1 		$7.5M Buy
1,000,562
+783,681
+361% +$6.32M 0.89% 40
2024
Q4 		$1.63M Sell
216,881
-247,167
-53% -$1.88M 0.22% 80
2024
Q3 		$3.53M Buy
464,048
+63,600
+16% +$483K 0.45% 60
2024
Q2 		$2.47M Buy
+400,448
New +$2.21M 0.33% 71
2022
Q2 		– Sell
-476,978
Closed -$7.76M – 80
2022
Q1 		$7.76M Buy
476,978
+76,977
+19% +$1.23M 2.27% 17
2021
Q4 		$5.54M Buy
400,001
+298,040
+292% +$3.94M 1.22% 29
2021
Q3 		$1.47M Sell
101,961
-250,000
-71% -$3.94M 0.37% 59
2021
Q2 		$5.57M Buy
351,961
+107,281
+44% +$1.46M 1.22% 31
2021
Q1 		$2.49M Sell
244,680
-293,690
-55% -$3.03M 0.58% 47
2020
Q4 		$4.01M Sell
538,370
-262,370
-33% -$1.35M 1.03% 40
2020
Q3 		$2.75M Sell
800,740
-99,868
-11% -$428K 0.73% 49
2020
Q2 		$4.29M Sell
900,608
-95,000
-10% -$379K 1.21% 33
2020
Q1 		$1.99M Sell
995,608
-145,604
-13% -$401K 0.92% 37
2019
Q4 		$3.94M Buy
+1,141,212
New +$2.87M 1.14% 32

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Parkman Healthcare Partners's BCRX Position: Q1 2026 in Review

Parkman Healthcare Partners increased its BioCryst Pharmaceuticals (BCRX) stake by 90% in Q1 2026, buying an estimated $6.28M and bringing the position to 1,708,099 shares worth $16.3M. The position accounts for 1.68% of the portfolio, ranked #20.

Parkman Healthcare Partners first reported a position in BCRX in Q4 2019 and has held it in 18 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Parkman Healthcare Partners held 1,708,099 shares of BioCryst Pharmaceuticals worth $16.3M as of Q1 2026.
  • Parkman Healthcare Partners bought 808,042 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $6.28M.
  • BioCryst Pharmaceuticals made up 1.68% of Parkman Healthcare Partners's portfolio in Q1 2026, its #20 holding.
  • Parkman Healthcare Partners first reported a position in BioCryst Pharmaceuticals in Q4 2019 and has held it in 18 quarters since.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.